Exploring the Anti-ageing Effects of Metformin in COPD

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

212

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

May 1, 2029

Study Completion Date

September 1, 2029

Conditions

COPD

Interventions

DRUG

Metformin 850Mg Tab

Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.

OTHER

Placebo

Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.

All Listed Sponsors

lead

Fundación Instituto de Investigación Sanitaria de Navarra

OTHER